Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 07 02:25PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-0.38 Insider Own1.30% Shs Outstand14.41M Perf Week0.55%
Market Cap26.37M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float14.22M Perf Month-0.54%
Income-5.42M PEG- EPS next Q- Inst Own50.59% Short Float / Ratio1.51% / 9.96 Perf Quarter-10.73%
Sales0.00M P/S- EPS this Y- Inst Trans11.50% Short Interest0.21M Perf Half Y-11.59%
Book/sh2.63 P/B0.69 EPS next Y- ROA-12.89% Target Price17.00 Perf Year-12.85%
Cash/sh2.67 P/C0.69 EPS next 5Y- ROE-13.44% 52W Range1.74 - 2.70 Perf YTD-22.78%
Dividend- P/FCF- EPS past 5Y53.56% ROI-14.20% 52W High-32.22% Beta1.25
Dividend %- Quick Ratio39.21 Sales past 5Y0.00% Gross Margin- 52W Low5.47% ATR0.07
Employees6 Current Ratio39.21 Sales Q/Q- Oper. Margin0.00% RSI (14)43.82 Volatility4.12% 3.93%
OptionableYes Debt/Eq0.01 EPS Q/Q38.97% Profit Margin- Rel Volume1.11 Prev Close1.83
ShortableYes LT Debt/Eq0.01 EarningsOct 18 AMC Payout- Avg Volume21.54K Price1.83
Recom1.00 SMA20-0.65% SMA50-4.57% SMA200-9.62% Volume18,421 Change0.00%
Date Action Analyst Rating Change Price Target Change
Feb-27-18Initiated Ascendiant Capital Markets Buy $2
Oct-09-13Initiated Dawson James Buy $3.75
Oct-18-23 04:25PM
Jul-21-23 04:25PM
Jul-13-23 11:30AM
Apr-24-23 04:25PM
Feb-24-23 04:20PM
10:19AM Loading…
Feb-03-23 10:19AM
Dec-19-22 04:05PM
Nov-14-22 09:24AM
Oct-28-22 04:15PM
Aug-02-22 04:15PM
Jul-18-22 06:14AM
Jun-21-22 04:05PM
May-05-22 04:15PM
May-02-22 04:15PM
Apr-18-22 04:30PM
01:35AM Loading…
Apr-05-22 01:35AM
Apr-01-22 07:09AM
Mar-31-22 04:15PM
Mar-14-22 04:15PM
Mar-07-22 04:30PM
Feb-08-22 04:21AM
Jan-04-22 08:30AM
Dec-02-21 08:30AM
Nov-20-21 07:01AM
Nov-09-21 04:15PM
Nov-02-21 04:15PM
Oct-29-21 07:03AM
Oct-28-21 04:30PM
Sep-16-21 08:30AM
08:05AM Loading…
Aug-16-21 08:05AM
Aug-12-21 01:15AM
Aug-09-21 08:00AM
Aug-04-21 04:15PM
Jul-28-21 08:00AM
Jul-13-21 08:00AM
Jul-09-21 08:00AM
Jul-08-21 11:20AM
Jul-07-21 08:00AM
Jun-23-21 09:35AM
May-11-21 04:15PM
May-05-21 04:05PM
May-03-21 04:30PM
Mar-18-21 04:30PM
Feb-13-21 01:09AM
Dec-15-20 08:30AM
Dec-09-20 05:40PM
Nov-23-20 12:28PM
Nov-02-20 08:30AM
Oct-07-20 08:30AM
Oct-05-20 04:30PM
Sep-21-20 08:00AM
Aug-17-20 08:49AM
Aug-12-20 08:00AM
Aug-05-20 04:15PM
Jul-07-20 08:30AM
Jun-03-20 09:56AM
Jun-01-20 08:20AM
May-29-20 12:24PM
May-28-20 04:19PM
May-07-20 08:30AM
May-06-20 04:30PM
Feb-18-20 04:30PM
Feb-01-20 08:31AM
Nov-06-19 04:10PM
Nov-03-19 08:47AM
Sep-12-19 08:30AM
Sep-11-19 08:30AM
Sep-04-19 01:37PM
Aug-21-19 09:49AM
Aug-01-19 04:30PM
Jun-04-19 07:09AM
May-13-19 09:00AM
May-08-19 04:30PM
May-01-19 08:30AM
Apr-23-19 08:30AM
Mar-18-19 08:30AM
Mar-06-19 08:00AM
Feb-27-19 04:15PM
Feb-20-19 07:30AM
Jan-16-19 08:30AM
Dec-26-18 11:47AM
Dec-20-18 04:01PM
Nov-14-18 04:30PM
Nov-12-18 08:30AM
Nov-05-18 08:30AM
Oct-10-18 04:16PM
Oct-02-18 08:00AM
Sep-18-18 08:30AM
Aug-09-18 04:15PM
Aug-03-18 09:45AM
Jul-31-18 12:15PM
ARCA biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of targeted therapies for cardiovascular diseases. The firm focuses on the cardiovascular pathophysiology, molecular genetics, and clinical development. Its product candidate, Gencaro is a pharmacologic beta-blocker and mild vasodilator, which is developed for the treatment of chronic heart failure and other indications. The company was founded by Michael R. Bristow and Christopher David Ozeroff in 1992 and is headquartered in Westminster, CO.